| Abstract [eng] |
Ievos Kiliūtės master’s thesis scientific supervisor Doc. Dr. Kristina Garuolienė; Vilnius University, Faculty of Medicine, Institute of Biomedical Sciences, Pharmacy and Pharmacology Center, Vilnius. Master's thesis topic: Research on the Consumption of Proton Pump Inhibitors in Lithuania in 2022. The aim of the research: Based on electronic prescriptions issued in 2022, to analyze the trends in the use of proton pump inhibitors in Lithuania according to age, indications and municipalities. Tasks of the Research: To determine the prescribing of PPIs to the Lithuanian population in 2022 by analyzing electronic prescriptions. To analyze the consumption of proton pump inhibitors in four age groups (0-17, 18-44, 45-64 and 65 or older). To determine the main indications for which PPIs were prescribed in Lithuania in 2022. To discuss the prescribing trends of this drug class among prescribing specialists in Lithuania in 2022. To compare PPI consumption trends in Lithuanian municipalities in 2022. Research methods: Descriptive, Single-Moment Cross-Sectional Study: To determine the trends of PSI prescribing among different age groups, different municipalities, evaluating the trends of PSI prescribing in Lithuania in 2022. Statistical Analysis: Conducted using the "SPSS" program. Research results: Esomeprazole is the most used PPI in Lithuania (number of e-prescriptions for esomeprazole: 34.58%), (p < 0,05). The lowest number of prescriptions issued in 2022 was for rabeprazole and lansoprazole (1.54% each). Although the population group aged 65 and older is not the largest in Lithuania, it is still the main group in PPI consumption. In the children's age group (0-17), PPI consumption was the lowest. The total determined daily dose of PPI per 1,000 inhabitants of Lithuania = 1,865. Compared to previous years, PPI consumption has increased. The main indications established in Lithuania: K21.9, K21.0, K29.90, B96.81, K29.70. The consumption of proton pump inhibitors varies across Lithuanian municipalities. Evaluating the total PPI consumption among municipalities, PPI consumption is three times higher in Rokiškis district municipality than in Plungė district municipality (15.15 vs. 4.66). Inconsistencies in use are also observed between different PPIs. Omeprazole and esomeprazole were very unevenly used, while other proton pump inhibitors showed similar usage trends. Conclusions: The consumption of esomeprazole in Lithuania was the highest in 2022, with minimal consumption of rabeprazole and lansoprazole. The highest PPI consumption in Lithuania in 2022 was in the older age category (65 years and older) and the lowest in the age group of children (0-17 years). The main indications for PPI use in Lithuania in 2022 were: K21.9: GERD without esophagitis K21.0: GERD with esophagitis The highest PPI consumption was in Rokiškis district municipality (15.15 DDD/1000 inhabitants) and the lowest in Plungė district municipality (4.66 DDD/1000 inhabitants). The greatest disparities in PPI consumption among Lithuanian municipalities were observed with omeprazole and esomeprazole. In Lithuania, family doctors are more inclined to prescribe omeprazole, while gastroenterologists tend to prescribe esomeprazole. |
